• BioArctic announced new clinical and real-world evidence on Alzheimer’s drug lecanemab will be presented at AAIC 2026 in London, July 12-15.
• Updates will cover a subcutaneous formulation, longer-term use across patient groups, maintenance dosing, at-home administration, safety management, biomarker effects.
• Key readout includes the LEADER retrospective real-world study of US clinical practice three years post-approval, including maintenance IV dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202606300200BITN____UKPR__EN_20260629-BIT-3066-0) on June 30, 2026, and is solely responsible for the information contained therein.